vs
JBT Marel Corp（JBTM）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
JBT Marel Corp的季度营收约是Royalty Pharma plc的1.6倍（$1.0B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 5.3%，领先29.2%），JBT Marel Corp同比增速更快（115.6% vs 4.8%），过去两年JBT Marel Corp的营收复合增速更高（60.3% vs 4.6%）
JBT Marel Corp（原称JBT公司、约翰宾技术公司）是主营食品加工机械及自动化车辆的企业，2008年由FMC技术公司拆分非能源业务独立注册成立，总部位于美国伊利诺伊州芝加哥，发展历史可追溯至1884年加州洛斯加托斯果园主约翰·宾创办的企业。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
JBTM vs RPRX — 直观对比
营收规模更大
JBTM
是对方的1.6倍
$622.0M
营收增速更快
JBTM
高出110.8%
4.8%
净利率更高
RPRX
高出29.2%
5.3%
两年增速更快
JBTM
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $622.0M |
| 净利润 | $53.1M | $214.2M |
| 毛利率 | 34.5% | — |
| 营业利润率 | 7.2% | 62.4% |
| 净利率 | 5.3% | 34.4% |
| 营收同比 | 115.6% | 4.8% |
| 净利润同比 | 858.6% | 2.9% |
| 每股收益（稀释后） | $1.04 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收JBTMRPRX
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $934.8M | $578.7M | ||
| Q1 25 | $854.1M | $568.2M | ||
| Q4 24 | $467.6M | $593.6M | ||
| Q3 24 | $453.8M | $564.7M | ||
| Q2 24 | $402.3M | $537.3M | ||
| Q1 24 | $392.3M | $568.0M |
净利润JBTMRPRX
| Q4 25 | $53.1M | $214.2M | ||
| Q3 25 | $66.0M | $288.2M | ||
| Q2 25 | $3.4M | $30.2M | ||
| Q1 25 | $-173.0M | $238.3M | ||
| Q4 24 | $-7.0M | $208.2M | ||
| Q3 24 | $38.9M | $544.0M | ||
| Q2 24 | $30.7M | $102.0M | ||
| Q1 24 | $22.8M | $4.8M |
毛利率JBTMRPRX
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.9% | — | ||
| Q2 25 | 35.8% | — | ||
| Q1 25 | 34.2% | — | ||
| Q4 24 | 38.4% | — | ||
| Q3 24 | 36.1% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 35.8% | — |
营业利润率JBTMRPRX
| Q4 25 | 7.2% | 62.4% | ||
| Q3 25 | 10.2% | 70.1% | ||
| Q2 25 | 5.2% | 36.3% | ||
| Q1 25 | -3.9% | 94.0% | ||
| Q4 24 | 3.4% | 60.9% | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 6.7% | 50.2% | ||
| Q1 24 | 7.4% | -13.0% |
净利率JBTMRPRX
| Q4 25 | 5.3% | 34.4% | ||
| Q3 25 | 6.6% | 47.3% | ||
| Q2 25 | 0.4% | 5.2% | ||
| Q1 25 | -20.3% | 41.9% | ||
| Q4 24 | -1.5% | 35.1% | ||
| Q3 24 | 8.6% | 96.3% | ||
| Q2 24 | 7.6% | 19.0% | ||
| Q1 24 | 5.8% | 0.8% |
每股收益（稀释后）JBTMRPRX
| Q4 25 | $1.04 | $0.49 | ||
| Q3 25 | $1.26 | $0.67 | ||
| Q2 25 | $0.07 | $0.07 | ||
| Q1 25 | $-3.35 | $0.55 | ||
| Q4 24 | $-0.22 | $0.46 | ||
| Q3 24 | $1.21 | $1.21 | ||
| Q2 24 | $0.95 | $0.23 | ||
| Q1 24 | $0.71 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $618.7M |
| 总债务越低越好 | $1.5B | $9.0B |
| 股东权益账面价值 | $4.5B | $9.7B |
| 总资产 | $8.2B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资JBTMRPRX
| Q4 25 | $167.9M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $1.2B | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $843.0M |
总债务JBTMRPRX
| Q4 25 | $1.5B | $9.0B | ||
| Q3 25 | $1.5B | $8.9B | ||
| Q2 25 | $1.5B | $8.0B | ||
| Q1 25 | $2.0B | $7.6B | ||
| Q4 24 | $1.3B | $7.6B | ||
| Q3 24 | $648.3M | $7.6B | ||
| Q2 24 | $647.7M | $7.6B | ||
| Q1 24 | $647.0M | $6.1B |
股东权益JBTMRPRX
| Q4 25 | $4.5B | $9.7B | ||
| Q3 25 | $4.4B | $9.6B | ||
| Q2 25 | $4.4B | $9.5B | ||
| Q1 25 | $4.1B | $9.8B | ||
| Q4 24 | $1.5B | $10.3B | ||
| Q3 24 | $1.6B | $10.3B | ||
| Q2 24 | $1.5B | $9.8B | ||
| Q1 24 | $1.5B | $9.9B |
总资产JBTMRPRX
| Q4 25 | $8.2B | $19.6B | ||
| Q3 25 | $8.2B | $19.3B | ||
| Q2 25 | $8.3B | $18.3B | ||
| Q1 25 | $8.0B | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $2.8B | $18.0B | ||
| Q2 24 | $2.7B | $17.7B | ||
| Q1 24 | $2.7B | $16.1B |
负债/权益比JBTMRPRX
| Q4 25 | 0.33× | 0.92× | ||
| Q3 25 | 0.34× | 0.93× | ||
| Q2 25 | 0.35× | 0.84× | ||
| Q1 25 | 0.48× | 0.78× | ||
| Q4 24 | 0.81× | 0.74× | ||
| Q3 24 | 0.41× | 0.74× | ||
| Q2 24 | 0.43× | 0.78× | ||
| Q1 24 | 0.43× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $83.5M | — |
| 自由现金流率自由现金流/营收 | 8.3% | — |
| 资本支出强度资本支出/营收 | 3.4% | — |
| 现金转化率经营现金流/净利润 | 2.21× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $238.1M | — |
8季度趋势，按日历期对齐
经营现金流JBTMRPRX
| Q4 25 | $117.4M | $827.1M | ||
| Q3 25 | $87.7M | $702.6M | ||
| Q2 25 | $102.2M | $364.0M | ||
| Q1 25 | $34.4M | $596.1M | ||
| Q4 24 | $128.7M | $742.5M | ||
| Q3 24 | $71.9M | $703.6M | ||
| Q2 24 | $21.6M | $658.2M | ||
| Q1 24 | $10.4M | $664.6M |
自由现金流JBTMRPRX
| Q4 25 | $83.5M | — | ||
| Q3 25 | $56.5M | — | ||
| Q2 25 | $83.7M | — | ||
| Q1 25 | $14.4M | — | ||
| Q4 24 | $118.7M | — | ||
| Q3 24 | $65.0M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $-100.0K | — |
自由现金流率JBTMRPRX
| Q4 25 | 8.3% | — | ||
| Q3 25 | 5.6% | — | ||
| Q2 25 | 9.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 25.4% | — | ||
| Q3 24 | 14.3% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | -0.0% | — |
资本支出强度JBTMRPRX
| Q4 25 | 3.4% | — | ||
| Q3 25 | 3.1% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 2.6% | — | ||
| Q1 24 | 2.7% | — |
现金转化率JBTMRPRX
| Q4 25 | 2.21× | 3.86× | ||
| Q3 25 | 1.33× | 2.44× | ||
| Q2 25 | 30.06× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.85× | 1.29× | ||
| Q2 24 | 0.70× | 6.45× | ||
| Q1 24 | 0.46× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBTM
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
